Background: Pancreatogenic diabetes, a consequence of pancreatic tissue loss following pancreatectomy, poses a significant challenge for patients undergoing pancreatic surgery. Islet autotransplantation (IAT) offers a promising approach to prevent or alleviate pancreatogenic diabetes, but its application has been limited to individuals with painful chronic pancreatitis.
Methods: This study presents a 15-y clinical experience with the Milan Protocol, which expands IAT after pancreatectomy to a broader spectrum of patients with malignant and nonmalignant pancreatic diseases. The analysis evaluates feasibility, efficacy, and safety of IAT. Modified Igls criteria validated through the arginine test and mixed meal tolerance tests were used to assess long-term metabolic outcomes.
Results: Between November 2008 and June 2023, IAT procedures were performed on 114 of 147 candidates. IAT-related complications occurred in 19 of 114 patients (16.7%), with 5 being potentially serious. Patients exhibited sustained C-peptide secretion over the 10-y follow-up period, demonstrating a prevalence of optimal and good beta-cell function. Individuals who underwent partial pancreatectomy demonstrated superior metabolic outcomes, including sustained C-peptide secretion and a reduced risk of developing diabetes or insulin dependence compared with those who underwent total pancreatectomy. For patients who had total pancreatectomy, the quantity of infused islets and tissue volume were identified as critical factors influencing metabolic outcomes. An increased risk of recurrence or progression of baseline diseases was not observed in subjects with neoplasms.
Conclusions: These findings provide valuable insights into the benefits and applications of IAT as a therapeutic option for pancreatogenic diabetes after pancreatic surgery, expanding its potential beyond painful chronic pancreatitis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335085 | PMC |
| http://dx.doi.org/10.1097/TP.0000000000005037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Accuracy and feasibility of continuous glucose monitoring system in pancreatectomy patients.
Langenbecks Arch Surg
January 2025
Department of Surgery, Division of HBP Surgery & Liver Transplantation, Korea University College of Medicine, Seoul, Korea.
Purpose: Pancreatectomy patients often experience challenging fluctuations in blood glucose levels; therefore, they require a reliable monitoring system. This study aimed to determine the accuracy and acceptability of a continuous glucose monitoring (CGM) system compared with the intermittent capillary glucose test in patients who have undergone pancreatectomy.
Methods: Thirty non-diabetic pancreatectomy patients participated.
Pancreatogenic (Type 3c) Diabetes Revealed by Diabetic Ketoacidosis.
Cureus
December 2024
Internal Medicine, Coimbatore Medical College, Coimbatore, IND.
Pancreatogenic diabetes also known as type 3c diabetes mellitus (DM) is a distinct entity often overlooked and misdiagnosed as type 2 diabetes. It results from exocrine pancreatic dysfunction involving both insulin and glucagon deficiencies due to damage to pancreatic beta and alpha cells. This case highlights a 46-year-old male presenting with diabetic ketoacidosis (DKA), a rare but severe complication of type 3c DM.
View Article and Find Full Text PDFCentral pancreatectomy: An uncommon but potentially optimal choice of pancreatic resection.
Hepatobiliary Pancreat Dis Int
November 2024
Department of Academic Surgery, The Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London SW3 6JJ, UK; Department of HPB Surgery, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Infirmary, Upper Maudlin St, Bristol BS2 8HW, UK. Electronic address:
Benign, premalignant or low-grade malignant pancreatic tumors are increasingly diagnosed owing to the widespread uptake of cross-sectional imaging. Surgical excision is a potential treatment option for these tumors. Pancreatoduodenectomy and distal pancreatectomy are the standard resections for tumors located in the pancreatic head-neck or body-tail, respectively, and not uncommonly sacrifice a significant amount of healthy pancreatic parenchyma.
View Article and Find Full Text PDFGlycemic Variability in Pancreatogenic Diabetes Mellitus: characteristics, Risks, Potential Mechanisms, and Treatment Possibilities.
Int J Gen Med
September 2024
Department of Endocrinology, Gusu School, Nanjing Medical University, The First People's Hospital of Kunshan, Kunshan, 215300, People's Republic of China.
Article Synopsis
- Pancreatogenic diabetes mellitus is becoming more prominent due to its high rates of occurrence, complications, and mortality, with glycemic variability (GV) being a key risk factor.
- Effective management of GV is essential for preventing this type of diabetes and improving patient outcomes, yet many patients receive inadequate or potentially harmful medications.
- This study aims to explore the connection between GV and pancreatogenic diabetes, investigate underlying mechanisms, and offer lifestyle tips and better medication choices for managing GV in affected patients.
Spontaneous Hypoglycemia in a Non-diabetic Patient: A Diagnostic and Therapeutic Conundrum.
Cureus
July 2024
Internal Medicine, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra Institute of Higher Education and Research, Chennai, IND.
Article Synopsis
- * After ruling out common causes like insulin use and sepsis, other potential causes, such as nesidioblastosis (a rare form of hypoglycemia), should be investigated.
- * A case study of a non-diabetic male with symptoms like dizziness and palpitations revealed that he had nesidioblastosis instead of insulinoma, demonstrating the importance of thorough evaluation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!